Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 592

1.

Nurse-like cells in rheumatoid arthritis - Formation of survival niches cooperating between the cell types.

Ochi T, Sawai T, Murakami K, Kamataki A, Uzuki M, Tomita T, Tsuboi H, Ochi K, Ebina K, Hirohata S, Lipsky PE.

Mod Rheumatol. 2018 May 31:1-15. doi: 10.1080/14397595.2018.1483305. [Epub ahead of print]

PMID:
29848137
2.

Aberrant Expansion and Function of T Follicular Helper Cell Subsets in IgG4-Related Disease.

Chen Y, Lin W, Yang H, Wang M, Zhang P, Feng R, Chen H, Peng L, Zhang X, Zhao Y, Zeng X, Zhang F, Zhang W, Lipsky PE.

Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40556. [Epub ahead of print]

PMID:
29781221
3.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 May 5. pii: annrheumdis-2018-213582. doi: 10.1136/annrheumdis-2018-213582. [Epub ahead of print] No abstract available.

PMID:
29730639
4.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 May 5. pii: annrheumdis-2018-213558. doi: 10.1136/annrheumdis-2018-213558. [Epub ahead of print] No abstract available.

PMID:
29730638
5.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Apr 28. pii: annrheumdis-2018-213537. doi: 10.1136/annrheumdis-2018-213537. [Epub ahead of print] No abstract available.

PMID:
29705742
6.

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.

Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.

Arthritis Rheumatol. 2018 Apr 12. doi: 10.1002/art.40522. [Epub ahead of print]

PMID:
29648686
7.

Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.

Zhou YZ, Zhao LD, Chen H, Zhang Y, Wang DF, Huang LF, Lv QW, Liu B, Li Z, Wei W, Li H, Liao X, Liu H, Liu X, Jin H, Wang J, Fei YY, Wu QJ, Zhang W, Shi Q, Zheng WJ, Zhang FC, Tang FL, Lipsky PE, Zhang X.

Arthritis Res Ther. 2018 Apr 10;20(1):70. doi: 10.1186/s13075-018-1563-6.

8.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Mar 28. pii: annrheumdis-2018-213399. doi: 10.1136/annrheumdis-2018-213399. [Epub ahead of print] No abstract available.

PMID:
29592916
9.

The Role of ANA Determinations in Classification Criteria for SLE.

Pisetsky DS, Lipsky PE.

Arthritis Care Res (Hoboken). 2018 Mar 26. doi: 10.1002/acr.23559. [Epub ahead of print]

PMID:
29579355
10.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
11.

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.

Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE.

Arthritis Res Ther. 2017 Aug 17;19(1):191. doi: 10.1186/s13075-017-1396-8.

12.

Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases.

Grammer AC, Lipsky PE.

Rheum Dis Clin North Am. 2017 Aug;43(3):467-480. doi: 10.1016/j.rdc.2017.04.010. Review.

PMID:
28711146
13.

Mechanisms That Shape Human Antibody Repertoire Development in Mice Transgenic for Human Ig H and L Chain Loci.

Longo NS, Rogosch T, Zemlin M, Zouali M, Lipsky PE.

J Immunol. 2017 May 15;198(10):3963-3977. doi: 10.4049/jimmunol.1700133. Epub 2017 Apr 24.

14.

Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease.

Lin W, Zhang P, Chen H, Chen Y, Yang H, Zheng W, Zhang X, Zhang F, Zhang W, Lipsky PE.

Arthritis Res Ther. 2017 Feb 10;19(1):25. doi: 10.1186/s13075-017-1231-2.

15.
16.

Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.

Dörner T, Lipsky PE.

Nat Rev Rheumatol. 2016 Nov;12(11):645-657. doi: 10.1038/nrrheum.2016.158. Epub 2016 Oct 13. Review.

PMID:
27733759
17.

Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis.

Grammer AC, Ryals MM, Heuer SE, Robl RD, Madamanchi S, Davis LS, Lauwerys B, Catalina MD, Lipsky PE.

Lupus. 2016 Sep;25(10):1150-70. doi: 10.1177/0961203316657437. Review.

PMID:
27497259
18.

A critical review of clinical trials in systemic lupus erythematosus.

Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R.

Lupus. 2016 Sep;25(10):1122-40. doi: 10.1177/0961203316652492. Review.

19.

Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.

Fleischer SJ, Daridon C, Fleischer V, Lipsky PE, Dörner T.

Arthritis Rheumatol. 2016 May;68(5):1210-21. doi: 10.1002/art.39559.

20.

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.

Dörner T, Shock A, Goldenberg DM, Lipsky PE.

Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23. Review.

Supplemental Content

Loading ...
Support Center